Article updated on:
December 13, 2023
DVC Stem employs a dedicated team of medical professionals, tasked with verifying the accuracy of health claims and summaries of medical research. Each member's expertise is aligned with the subject matter of the article to ensure precision and relevance.
We evaluate medical studies published in reputable scientific journals to form our opinions on a product or health matter, ensuring the utmost scientific precision.
Join our newsletter to learn more about stem cell therapy and the science behind it.
Exploring the promising potential of mesenchymal stem cells (MSCs) in treating Multiple Sclerosis, stem cell therapy offers a groundbreaking approach to managing MS.
This innovative treatment targets inflammation and immune regulation, potentially enhancing patients' quality of life through improved energy, mobility, and essential function control.
Understand the transformative power of MSCs in combating MS symptoms and halting disease progression.
Stem Cell Therapy for MS
Stem cell therapy is a new MS infusion treatment aimed at improving disease state by reducing inflammation and regulating immune cells.
Stem cell therapy for MS, specifically the administration of mesenchymal stem cells (MSCs) for Multiple Sclerosis, has demonstrated great potential to help improve symptoms and stabilize condition progression.
The immunomodulatory (ability to regulate the immune system), tissue-protective, and repair-promoting properties of MSCs demonstrated in multiple models make them an attractive therapy for Multiple Sclerosis (MS) and other conditions characterized by inflammation/or tissue injury.
MS Patients may be able to expect an increase in energy, flexibility, strength, mobility, and control of essential functions. Data is also beginning the show that mesenchymal stem cells (MSCs) administered intravenously may have the ability to halt disease progression for an extended period. (2)
Mesenchymal stem cells (MSCs) have shown promise as a potential treatment for multiple sclerosis (MS) due to their immunomodulatory and neuroprotective effects. MSCs can be derived from various sources, such as umbilical cord, adipose tissue, and bone marrow, and have demonstrated positive effects in clinical trials of Multiple Sclerosis.
Some key benefits of MSCs in MS treatment include:
- Immunomodulation: MSCs can modulate the immune response by suppressing the activation and function of autoreactive T cells, which play a significant role in MS pathogenesis.
- Neuroprotection: MSCs can protect neurons from damage by reducing inflammation, promoting neuronal integrity, and providing a suitable environment for neuron regeneration and remyelination.
- Potential for combination therapy: Combining MSCs with other treatments, such as IFNβ, may enhance their immunomodulatory and regenerative effects, providing greater benefits for MS patients.
Third-Party Efficacy Data
Based on the provided search results, several clinical trials have been conducted to evaluate the safety and efficacy of mesenchymal stem cells (MSCs) as a potential treatment for multiple sclerosis (MS):
- Small early-phase trials showed that single intravenous infusions of autologous bone marrow-derived MSCs were safe and well-tolerated in MS patients. Some beneficial effects on inflammatory markers, immune cell populations, and MRI lesions were observed.
- Larger phase 1/2 trials using repeated intravenous injections of autologous MSCs (e.g. MESEMS, NCT01606215) also demonstrated safety and some indications of positive effects on disability scores and inflammatory parameters.
- A long-term 4 year study administering multiple courses of MSCs intravenously to patients with progressive MS found the treatment was safe and associated with stabilization or improvement in disability scores in most patients.
- Studies have also evaluated different MSC sources (bone marrow, adipose tissue, umbilical cord), doses, delivery methods, and frequency/timing of administration. Optimal protocols are still being determined.
In summary, MSC therapy for MS has been extensively studied in clinical trials and shown to be safe and well-tolerated. While results are promising, larger randomized placebo-controlled trials with longer follow-ups are still needed to conclusively demonstrate efficacy, especially for long-term outcomes.
Internal Efficacy Data (Success Rate)
As DVC Stem, we are pioneering regenerative medicine through our IRB-approved clinical study evaluating the use of cultured expanded allogeneic, cord-derived mesenchymal stem cells (MSCs) as a treatment for chronic inflammation. We have recently collected some preliminary data on the efficacy of our stem cell protocol in MS patients.
The data was gathered from patients' responses to PARQ questionnaires administered at 3, 6, 9, and 12 months following MSC treatment. The questionnaires measured percentage improvement from baseline in various parameters related to memory, physical abilities, sensory function, cognition, libido, sleep quality, and motivation.
Our initial 12-month results demonstrate promising improvements in many of these areas, with the most robust gains seen at 9 months post-treatment before tapering off slightly at 12 months. In particular, physical fitness, energy, balance, coordination, reaction time, and stamina showed over 50% enhancement at 9 months. Measures like memory and flexibility were more inconsistent.
While these preliminary findings are encouraging, our trial is limited by the lack of a control group and small sample size so far, preventing definitive conclusions about efficacy and long-term outcomes. We are continuing to enroll patients to expand our data set and are following participants beyond 12 months to better understand the durability of benefits.
However, further research is needed and we look forward to sharing additional efficacy and safety data as our trial progresses. Our goal is to thoroughly assess our stem cell platform to determine if it can transform treatment for MS and other degenerative conditions.
Can stem cells regrow myelin?
Mesenchymal stem cells (MSCs) have shown potential in repairing myelin damage in various studies. Mesenchymal stem cells (MSCs) can promote remyelination and improve myelin repair when transplanted into animal models of demyelination. They are thought to help by supplying growth factors and cytokines that support oligodendrocyte function and differentiation. Neural stem cells from the subventricular zone of the brain can generate new oligodendrocytes capable of remyelination.
This makes MSCs the newest treatment option for MS as they may help to reduce inflammation and slow or even stop the progression of the disease.
Can stem cells reverse nerve damage?
Another study published in Stem Cell Research & Therapy in 2019 suggests that mesenchymal stem cells (MSCs) can protect nerve cells from damage by reducing inflammation and oxidative stress and promoting remyelination. (7)
It's important to note that stem cell therapy for MS is still in the early stages of research and development. Much more research is needed before it can be considered a standard treatment for MS. Additionally, clinical trials with MSCs are still ongoing. The therapy's long-term (5-10 years) efficacy is yet to be determined in third-party peer-reviewed studies.
Stem cell treatment for MS
Mesenchymal stem cell (MSC) therapy holds significant potential as a treatment option for Multiple Sclerosis (MS). While more research is needed to understand its long-term efficacy, peer-reviewed studies have shown promising results in reducing inflammation and promoting tissue repair in MS patients.
Stem cell treatment for Multiple Sclerosis has demonstrated healing and repair-promoting properties. Expanded cord tissue-derived umbilical cord cells have potentially made it possible to treat MS more effectively. Studies have been conducted on both secondary progressive ms and relapsing-remitting ms.
Mesenchymal stem cells (MSCs) are a natural treatment that can reduce inflammation within the body. Once administered, stem cells help regulate the immune system and prevent further myelin degradation. This makes mesenchymal stem cells (MSCs) an attractive therapy for MS and other conditions characterized by inflammation and/or tissue injury. DVC Stem has even seen patients report significant improvements in symptoms such as peripheral neuropathy.
Stem cell Multiple Sclerosis (MS) treatment advantages
- A growing amount of evidence supporting the ability of mesenchymal stem cells to help regulate the immune system
- Ability to repair damaged myelin sheath (remyelination) or neurons
- Umbilical cord tissue provides a high number of mesenchymal cells
- Stem cells are extremely anti-inflammatory, allowing for the repair and regeneration of tissue
- IV stem cell therapy is NOT invasive and does not require any downtime
- Reduction of debilitating MS symptoms
- Overall stabilization of the condition or extended periods of remission
What is the success rate of stem cell therapy for MS?
The success rate of mesenchymal stem cell (MSC) therapy for multiple sclerosis (MS) is still under investigation. Studies on using MSCs in MS have been limited and have shown primarily positive results. Studies for relapsing forms of MS have reported improvement in the symptoms of MS and reduced inflammation following MSC therapy.
A review of studies on MSC therapy for MS found that the treatment was generally safe, with few severe side effects reported. However, the review's authors noted that the studies included were small and had methodological limitations. Therefore, more research is needed to confirm the safety and efficacy of MSC therapy for MS.
How long does stem cell therapy last for MS?
The duration of the effects of stem cell therapy for Multiple Sclerosis (MS) is still under investigation. Studies on the use of stem cell therapy for MS have reported varying results, and there is currently no consensus on how long the effects of the treatment last.
Some studies have reported that the benefits of stem cell therapy for MS can last for several years, while others have found that the effects are more short-lived. The impact duration may depend on the type of stem cell therapy used, the stage of the disease, and the individual patient.
New treatments for MS: Phase II double-blind trial shows impressive results
A recent phase II double-blind trial, randomized and controlled by placebo study of 48 patients conducted in Isreal, found that mesenchymal stem cell therapy improved MS symptoms in roughly 73% of participants. At the same time, disease progression was halted entirely in approximately 60% of participants. (2)
According to Dr. Ibrahim Kassis: “Some patients stopped using a walker or a stick, and some others increased the distance they can walk”
The study evaluated treatment success by measuring participants' Expanded Disability Status Scale (EDSS scores before and after treatment. The study concluded that the mean EDSS score improved in the group treated with mesenchymal stem cells (MSCs)
"The mean EDSS score deteriorated in the sham-treated group and was improved in the MSC-IT and MSC-IV groups during both treatment cycles (P = 0.0002 and P = 0.007, respectively, versus sham treatment; Mann-Whitney test) (Fig. 2 and Table 3). Two patients showed improvement in EDSS during the first cycle of treatment with MSC-IT and 11 during the second cycle (ranging from 0.5 to 1.0 degrees). The respective numbers of patients with improvement in the MSC-IV group were three and six in the two cycles; one patient showed improvement in the sham treatment group (Table 4)." (2)
The study revealed positive results in all predefined primary endpoints. No serious, treatment-related adverse effects were observed, and significantly fewer patients in the MSC-IT and MSC-IV groups experienced treatment failure. (2) One of the researchers in this study, Petrou et al state:
"Overall, the robust effects of MSC transplantation on various parameters that reflect neurological dysfunction and especially on multiple sclerosis activity may indicate the involvement of (central and peripheral) immunomodulatory and possibly also neuroprotective mechanisms.
These benefits seem of particular clinical significance, as they were observed in patients with progressive multiple sclerosis unresponsive to conventional immunotherapies, and for which limited treatment options exist." This study found that mesenchymal stem cell transplantation did have an immunomodulatory effect that positively impacted the MS patients in the study.
Stem Cells and Multiple Sclerosis
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) with a solid degenerative component, leading to irreversible disability. Mesenchymal stem cells (MSCs) have been shown to prevent inflammation and neurodegeneration in MS.
"Mesenchymal stem cells (MSC) are stromal [precursor] cells residing in many tissues, including the bone marrow (BM), where they support hematopoiesis. Treatment with MSC improves the course of the preclinical model of MS, experimental autoimmune encephalomyelitis (EAE) when administered at early stages. In EAE, MSC has a profound anti-inflammatory and immune-modulating effect [5–9], but they also exhibit neuroprotective features and foster remyelination endogenous neurogenesis with scarce evidence of differentiation in neural cells" - Antonio Uccelli
Mesenchymal stem cells (MSCs) have immune regulatory properties that may have the ability to prevent the immune system from attacking the myelin sheath surrounding nerve fibers. Mesenchymal stem (MSCs) cells may be able to regenerate scar tissue (damaged myelin sheath) of the affected neurons. (also called remyelination)
Stem cell replacement to help Multiple Sclerosis (MS) at DVC Stem
The adult stem cells used at DVC Stem are sourced from ethically donated full-term human umbilical cord tissue (Allogeneic Mesenchymal Stem Cells). The tissue is only sourced from the American Association of Tissue Banks (AATB) and cultured and expanded in our cGMP, FDA 351 & 361 compliant, IRB-approved partner lab in the United States. This ensures that all human umbilical cord tissue is screened and tested for infectious disease and that the cells' expansion process follows US safety standards.
MS stem cell treatment cost
Is there a cure for Multiple Sclerosis (MS)?
Currently, there is no cure for Multiple Sclerosis (MS). Still, several treatments can be prescribed to manage the symptoms of MS. Unfortunately, these treatments can be pretty expensive and can reach upwards of $100,000 a year for the newest MS drugs. Studies have shown that disease-modifying therapies (DMTs) can improve the symptoms of Multiple Sclerosis by decreasing the frequency and severity of relapses and slowing the progression of the disease. Studies indicate that starting DMT treatment early after diagnosis can improve outcomes.
Is stem cell therapy a cure for MS?
Mesenchymal stem cell therapy is a promising alternative to traditional multiple sclerosis (MS) treatments. Mesenchymal stem cells (MSCs) are a type of stem cell that can differentiate into a variety of cell types, including nerve cells, and can suppress immune response; these cells have been investigated as a potential option to treat multiple sclerosis.
Current research for a Multiple Sclerosis cure
A study published in the Journal of Neuroimmunology in 2018 showed that an animal model of secondary progressive multiple sclerosis treatment with mesenchymal stem cells (MSCs) significantly reduced inflammation and improved neurological function. (6)
HSCT vs. Stem Cell Therapy
Mesenchymal stem cell therapy (MSCT) and HSCT are very different procedures. Hematopoietic stem cell transplantation (HSCT) should generally be considered a high-dose immunosuppressive therapy with hematopoietic stem cell support. Rather than an alternative type of stem cell therapy.
Mesenchymal stem cell therapy has shown similar outcomes to HSCT without the need for aggressive cytotoxic drugs (Chemotherapy). It is also important to note that cord tissue-derived mesenchymal stem cell therapy has shown the ability to avoid a negative response from a person’s immune system, allowing the cells to be transplanted in a wide range of people without fear rejection. These transplants vastly increase the body’s natural healing abilities and have potent anti-inflammatory and immunosuppressive responses.
Which treatment is more effective?
Many peer-reviewed studies have found that mesenchymal stem cell therapy (MSCT) has potent anti-inflammatory and immunosuppressive properties. In many different models, the intravenous administration of mesenchymal stem cells (MSCs) can improve the healing of neural, renal, and lung injuries. (7) Mesenchymal stem cell therapy (MSCT) also can induce large periods of remission and may help improve MS symptoms, including; loss of strength, mobility, flexibility, numbness, and overall mobility.
The two treatment options (HSCT & MSCT) aim to achieve the same outcome: prevent relapses and new MRI lesions, and improve disability.
Mesenchymal stem cell therapy (MSCT) aims to prevent relapses and new MRI lesions and improve disability without invasive cytotoxic immunosuppression therapy (Chemotherapy). MSCT can reduce inflammation and regulate the immune system, which is vital in helping improve MS symptoms and promote disease remission.
According to a recent study published by Regmi and colleagues:
"The immunosuppressive activities of MSCs are initiated by cell-to-cell contact and the release of immunoregulatory molecules. By doing so, MSCs can inhibit the proliferation and function of T cells, natural killer cells, B cells, and dendritic cells, and can also increase the proliferation of regulatory T cells." (5)
Choose the treatment that is right for you
Results for Hematopoietic Stem Cell Transplants (HSCT) have been mostly positive for autoimmune diseases, such as Multiple Sclerosis, in which the immune system attacks a patient’s body. The treatment “resets” the immune system, hoping to cease the effects of the disorder.
However, many patients may be turned off by chemotherapy and the inherent risks associated with such aggressive treatment. Some patients may be in too poor a condition to even attempt this form of therapy. Although safety has dramatically improved with experience, HSCT initially had a 1 in 100 death rate for participants.
Mesenchymal stem cell therapy (MSCT) is a much less invasive and radical procedure, having little impact on the patient. Mesenchymal stem cell therapy (MSCT) gives patients an option for effective treatment without the risk of chemotherapy or who may be too poor to undergo Hematopoietic Stem Cell Transplants HSCT. Additionally, the non-invasive nature of Mesenchymal Stem Cell Therapy (MSCT) allows for repeat treatment over time without continuous damage being done to the body.
So does the immune system need to be destroyed to help neurological conditions such as MS effectively?
No, it does not. Published studies have found that Mesenchymal stem cell therapy (MSCT) can reduce inflammation and regulate the immune system without invasive immunosuppressive treatments (chemotherapy). Mesenchymal stem cells also offer intrinsic benefits that hematopoietic stem cells do not, such as the ability to differentiate into a variety of cell types, the release of immunoregulatory molecules, promote the release of exosome and growth factors.
Are stem cells safe?
Umbilical cord tissue-derived mesenchymal stem cells do not have any risk of rejection within the body. They are youthful, immune-privileged, undifferentiated cells. There are no blood products associated with this type of MSC either, removing the need for a donor match, they are universally accepted. These cells seek out inflammation in the body and begin to heal the damaged tissue.
Mesenchymal cord tissue-derived stem cells have been administered thousands of times at clinics worldwide. There have never been any recorded instances of rejection (graft vs. host disease).
Want to learn more about stem cell therapy for MS at DVC Stem?
DVC Stem is a stem cell therapy pioneer, offering stem cell therapies for years, and has become a cornerstone of the medical tourism industry. Located in the tropical paradise of Grand Cayman in the Western Caribbean, we offer patients a nearby alternative to traveling long distances and to less ideal locations. Our protocols are IRB approved, and our cells come from regulated, US-based, FDA-compliant laboratories.
We seek to offer the highest quality products, the latest treatments for various conditions, and a world-class setting and service. We administer over 300 million cord tissue-derived mesenchymal stem cells via IV, our treatments are minimally invasive, and we offer interest-free financing for US residents.
Frequently Asked Questions
Where Can I Get Stem Cell Therapy for MS?
To get stem cell therapy for MS, interested individuals can participate in DVC Stem's active, patient-funded clinical study. This study offers a unique opportunity to receive a substantial dose of 300 million mesenchymal stem cells (MSCs), specifically designed to target the symptoms and progression of Multiple Sclerosis. Explore this pioneering option at DVC Stem for cutting-edge MS treatment.
What is the Best Treatment For Multiple Sclerosis?
Multiple Sclerosis (MS) currently has no cure, but treatments are available to manage symptoms and control the condition. The choice of treatment varies depending on the disease stage and specific symptoms experienced by the individual.
Treating MS Relapses
- Corticosteroids: These are used to reduce nerve inflammation during MS relapses. Common types include oral prednisone and intravenous methylprednisolone.
Managing Specific MS Symptoms
- Medications for Symptom Management: Drugs like Amantadine, Armodafinil, and Modafinil are prescribed to address particular symptoms of MS.
Reducing MS Relapses - Disease-Modifying Therapies
Goal: These therapies aim to lessen myelin sheath damage and scarring, associated with MS relapses, and potentially slow the progression of disability.
- Mesenchymal Stem Cell Therapy
- Teriflunomide (Aubagio)
- Dimethyl fumarate (Tecfidera)
- Diroximel fumarate (Vumerity)
- Beta interferons
- Natalizumab (Tysabri)
- Ocrelizumab (Ocrevus)
How Long Is The Average MS Attack?
Multiple Sclerosis (MS) attacks, also known as relapses or flare-ups, exhibit varying durations, affecting individuals differently. The length and severity of these attacks can differ significantly from one person to another and from one episode to the next.
Duration of MS Attacks
- Typical Duration: On average, a relapse lasts about eight weeks from onset to recovery.
- Range of Duration: Flare-ups can be as short as a few days or extend over weeks or months.
MS Disease Progression
- Early Stages - Relapsing-Remitting MS: Initially, patients often experience attacks followed by periods of full, partial, or no recovery.
- Later Stages - Secondary Progressive MS: Over time, MS may evolve into a form where symptoms progressively worsen without remitting periods. WebMD
(1) J Liang, H. (n.d.). Allogeneic mesenchymal stem CELLS transplantation in the treatment of multiple sclerosis - J Liang, H Zhang, B Hua, H Wang, J wang, z Han, L Sun, 2009. Retrieved February 23, 2021, from https://journals.sagepub.com/doi/abs/10.1177/1352458509104590
(2) Petrou, P., Kassis, I., Levin, N., Paul, F., Backner, Y., Benoliel, T., . . . Karussis, D. (2020, November 30). Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Retrieved February 23, 2021, from https://academic.oup.com/brain/article/143/12/3574/6012789?login=true
(3) V; U. (n.d.). Mesenchymal stem cells in health and disease. Retrieved February 23, 2021, from https://pubmed.ncbi.nlm.nih.gov/19172693/
(4) Uccelli, A., Laroni, A., Brundin, L., Clanet, M., Fernandez, O., Nabavi, S., . . . MESEMS study group. (2019, May 9). Mesenchymal stem cells for multiple SCLEROSIS (MESEMS): A Randomized, double-blind, CROSS-OVER Phase I/ii clinical trial WITH autologous mesenchymal stem cells for the therapy of multiple sclerosis. Retrieved February 23, 2021, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507027/#CR5
(5) Shobha Regmi, Shiva Pathak, Jong Oh Kim, Chul Soon Yong, Jee-Heon Jeong, Mesenchymal stem cell therapy for the treatment of inflammatory diseases: Challenges, opportunities, and future perspectives, European Journal of Cell Biology, Volume 98, Issues 5–8, 2019, 151041, ISSN 0171-9335, https://doi.org/10.1016/j.ejcb.2019.04.002. (http://www.sciencedirect.com/science/article/pii/S0171933519300378
(6) Mesenchymal stromal cells in the treatment of multiple sclerosis" by S. A. Meletis, et al., published in Stem Cell Research & Therapy in 2018.
(7) Mesenchymal stem cells for the treatment of multiple sclerosis" by S. Scholz, et al., published in The Journal of clinical investigation in 2019.
(8) Multiple sclerosis information page (no date) National Institute of Neurological Disorders and Stroke. U.S. Department of Health and Human Services. Available at: https://www.ninds.nih.gov/health-information/disorders/multiple-sclerosis (Accessed: January 17, 2023).